Stephen R.D. Johnston, MD, PhD, on Clinical Considerations When Prescribing Abemaciclib for Early Breast Cancer
Posted: Tuesday, September 29, 2020
Stephen R.D. Johnston, MD, PhD, of The Royal Marsden NHS Foundation Trust, talks about selecting patients and managing their long-term adverse events when prescribing abemaciclib for hormone receptor–positive high-risk early breast cancer—the first CDK4/6 inhibitor to improve invasive disease–free survival.
For more on this study, visit the Journal of Clinical Oncology.